Skip to main content

Faeth Therapeutics, Inc.

corporate_fare Company Profile

Faeth Therapeutics, Inc.

FTH·NASDAQ·Life Sciences·CIK 0001829802

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. On February 17, 2026, the company completed the acquisition of Faeth Therapeutics, a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. This acquisition integrated Faeth's lead asset, PIKTOR, into the company's pipeline. PIKTOR is a proprietary investigational all-oral combination of serabelisib and sapanisertib, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. In connection with the acquisition, the company received $200 million in gross proceeds from a private placement financing, referred to as the 2026 Private Placement. This financing was supported by a syndicate of investors, including B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, and Vivo Capital, to advance PIKTOR through key clinical milestones.

Faeth Therapeutics, Inc. (NASDAQ:FTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for FTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for FTH spans 10-Q, 8-K.

Recent high-impact activity:

  • Faeth Lands Roche Collaboration to Test PIKTOR With Giredestrant in Breast Cancer
  • PIKTOR Hits 33% Confirmed Response Rate in Advanced Endometrial Cancer Phase 2
  • Faeth 10-Q: $174.8M Cash Funds PIKTOR Trials Through Topline Data
  • Faeth Posts $20.4M Q3 Loss, Cash at $174.8M Ahead of Year-End PIKTOR Data
  • FDA Grants Fast Track to Faeth's Piktor Combo in Endometrial Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$21.09M
Diluted EPS
-$16.72
Op. Cash Flow
-$20.45M
Free Cash Flow
-$20.47M
Operating Income
-$22.29M
Cash & Equivalents
$8.67M
Debt / Equity
0.00×
Shares Outstanding
1.26M sh
Source: 10-K · filed 2026-06-02 · accession 0001193125-26-252637

Short Interest & Short Volume

6.31 days to cover

FINRA reported short interest of 2,730,889 shares in FTH as of the October 30, 2026 settlement, a 17.7% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 65.8% of FTH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,730,889 shares as of October 30, 2026
Change vs prior period▲ 17.7%
Days to cover6.31 at avg daily volume of 432,468
Daily short volume (FINRA facilities)65.8% of 195,300 shares on November 20, 2026
5-day average short volume45.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with F →
$7.88
52-week range · as of 2026-11-03 $7.45 – $42.14
Market cap
$203.65M
Volume
419.1K (0.7× avg)
3-mo avg 633.6K
Live data · 2026-11-22 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FTH - Latest Insights

FTH
Nov 16, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $7.88 info
Change: -$2.62 (-25%) info
Market Cap: $203.65M info
FTH
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $7.88 info
Change: -$14.62 (-65%) info
Market Cap: $203.65M info
FTH
Nov 03, 2026, 8:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.20
Real-time Price: $7.88 info
Change: -$11.32 (-59%) info
Market Cap: $203.65M info
FTH
Nov 03, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.23
Real-time Price: $7.88 info
Change: -$11.35 (-59%) info
Market Cap: $203.65M info
FTH
Aug 17, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $32.44
Real-time Price: $7.88 info
Change: -$24.56 (-76%) info
Market Cap: $203.65M info
FTH
Aug 04, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $7.88 info
Change: -$22.12 (-74%) info
Market Cap: $203.65M info
FTH
Aug 04, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $7.88 info
Change: -$22.12 (-74%) info
Market Cap: $203.65M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets